Grant ID RP240311
Awarded On February 21, 2024
Title Treatment planning of ADC therapy for ovarian cancer with molecular photoacoustic-ultrasonic imaging
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Richard Bouchard
Cancer Sites Ovary
Contracted Amount $1,049,859
Lay Summary

Despite significant advances in the treatment of ovarian cancer (OC), patients with recurrent metastatic malignancies still have poor outcomes, and most of these patients will experience disease relapse. For advanced or metastatic OC disease, platinum-based chemotherapy remains the primary backbone for systemic treatment. Unfortunately, platinum-resistant OC occur in about 20% of patients after first-line platinum-based chemotherapy. To address this problem, mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate (ADC) comprising a folate receptor alpha (FRa)-binding antibody, was recently granted FDA approval for patients suffering from platinum-resistant disease with high FRa expre...

Read More